Cell therapy advances for retinal disease

Article

First in-human study of human umbilical tissue-derivedcaeels as a therapy for retinal degenerative diseases shows promise.

In the first in-human study of human umbilical tissue-derived cells as cell-based therapy for retinal degenerative diseases, all seven patients tolerated the subretinal injection well and had no postoperative visual loss.

"One out of seven isn't very much, but if you're looking for any possible signal, that might be it," said Dr Francis, whose lab was the lead institution in the study. "Otherwise, patients didn't lose vision.

All of the participants had advanced retinitis pigmentosa (RP), no better than hand-motion vision. They were enrolled from three institutions in the US and underwent vitrectomy and single unilateral extramacular subretinal injection of an allogenic cellular product known as CNTO2476.

The cells were produced by the Stem Cell Organization, which is part of the J&J Biotechnology Center of Excellence, Centocor R&D Inc., which is now planning to move forward with studies of additional indications and additional trials.

Dr Francis reported the latest findings at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology. In this preliminary study, the three men and four women, with a median age of 62 years, received cell dosages ranging from 47500 to 470000 cells delivered transvitreally to the subretinal space through a retinotomy. Follow-up evaluations were conducted for more than 1 year.

Analysis of the results showed no evidence of immune rejection. Two patients developed postsurgical retinal detachments, which may have been related to non-closure of the retinotomy site.

Although the participants in a phase I study are typically normal, healthy individuals, the nature of this therapy, which required a vitrectomy, necessitated choosing subjects with a retinal degenerative condition, Dr Francis said.

"We thought that the chances of seeing efficacy were very limited, but because this was the first in-human use of cells in this manner, and certainly in the eye, we thought that they would be the target group," he continued. "If we were going to see efficacy, it would be in one of these retinal degenerations such as RP and possibly age-related macular degeneration (AMD)."

Although it was encouraging that there was no evidence of an immune rejection, the broader implication of the phase I study for the field of stem cell research was that these cells could be successfully implanted in the retina without a deleterious effect or immune response, Dr Francis said.

"This was the first and tentative, careful step into transplantation and use of stem cells for retinal disease, and the results were encouraging," he added. "It was a small and carefully planned step forward for the field."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Related Content
© 2025 MJH Life Sciences

All rights reserved.